Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

BACKGROUND: Neoadjuvant anti-PD-1 may improve outcomes for patients with resectable NSCLC and provides a critical window for examining pathologic features associated with response. Resections showing major pathologic response to neoadjuvant therapy, defined as ≤10% residual viable tumor (RVT), may p...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Oncol
Autors principals: Cottrell, T R, Thompson, E D, Forde, P M, Stein, J E, Duffield, A S, Anagnostou, V, Rekhtman, N, Anders, R A, Cuda, J D, Illei, P B, Gabrielson, E, Askin, F B, Niknafs, N, Smith, K N, Velez, M J, Sauter, J L, Isbell, J M, Jones, D R, Battafarano, R J, Yang, S C, Danilova, L, Wolchok, J D, Topalian, S L, Velculescu, V E, Pardoll, D M, Brahmer, J R, Hellmann, M D, Chaft, J E, Cimino-Mathews, A, Taube, J M
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6096736/
https://ncbi.nlm.nih.gov/pubmed/29982279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdy218
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars